

# ASX ANNOUNCEMENT

5 September 2022

## ANTERIS HOSTS AUSTRALIAN INTERVENTIONAL CARDIOLOGY EXPERTS AT MALAGA FACILITY

Anteris Technologies Ltd (ASX: AVR) announces it hosted a group of Australian interventional cardiology and TAVR (Transcatheter Aortic Valve Replacement) experts from across the country at its Malaga facility in Western Australia.

The interventional cardiologists were given a detailed technical overview of the DurAVR™ THV (Transcatheter Heart Valve) technology including DurAVR™ design, ADAPT® tissue science and the ComASUR™ Transfemoral Delivery System. The overview included a tour of the Company's facility to observe the R&D laboratories, ongoing testing and manufacturing operations for Anteris' clinical trial program.

This group of leading clinicians will partner with Anteris to pave the way to future commercialisation of the DurAVR™ THV system, refining the Company's clinical roadmap and improving investor engagement.

"The Company has unlocked the value of its core technology in the past year and physician engagement forms a critical aspect of value delivery. Presenting our Malaga facility in full-operational mode demonstrates our deep progress with our DurAVR™ THV program. We are continuing to expand our global physician engagement with senior interventional cardiologists and establish long-term collaborative relationships. Physician support and enthusiasm for our product will prove highly beneficial as we continue toward commercialization and regulatory access goals. As an Australian Medtech company it's critical that we add Australian physicians to our global group of world-leading doctors" commented Anteris CEO, Mr Wayne Paterson.

Brisbane-based interventional cardiologist Dr Karl Poon added, "Having had the privilege to have been one of the first to implant DurAVR™ THV and witnessing its superior haemodynamics first-hand, it is now great to see the science, research and ongoing development behind the technology."

"With the proven benefits of the ADAPT® tissue technology, we are on the cusp of something very exciting which may solve the issues of tissue valve deterioration. The early haemodynamics of DurAVR™ appear to be superior than currently available valves." Commented Professor Jayme Bennetts Flinders University and Director Cardiothoracic Surgery, Flinders Medical Centre.

The Company's Malaga facility manufactures the DurAVR™ THV, a proprietary 3D single-piece leaflet design that mimics a native aortic valve using its ADAPT® tissue technology. Over 35,000 ADAPT®-treated tissue devices have been sold and/or supplied globally to treat a wide range of structural heart conditions"

**ENDS**

**Anteris Technologies Ltd Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

**Customer Service**

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



For personal use only

### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

### **Authorisation and Additional information**

This announcement was authorised by the Board of Directors.

### **For more information:**

Deanne Curry

GRACosway

E: [investors@anteristech.com](mailto:investors@anteristech.com)

M: +61 414 388 997

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>